Moderna (MRNA) stock has fallen off in the post-pandemic period as demand for its COVID-19 vaccine — the company's primary commercial product — decreased significantly. Pfizer (PFE) recently lower
There is no easy way to select individual stocks. Measures of financial quality can highlight companies that are worth a closer look, but a decision to commit money must also take into consideration b
Moderna Inc. investors enjoyed a rare rally Tuesday as shares of the biotechnology company headed for their first gain in two weeks.
Moderna Therapeutics Inc (NASDAQ:MRNA) has teamed up with Texas-headquartered private precision medicine and molecular science firm Caris Life Sciences for a multi-year partnership to advance mRNA-bas
Moderna's earnings come out next month, and concerns are growing that they might not be all that strong. Revenue will decline sharply this year and it wouldn't be surprising if the company trims its f
Shares of Moderna Inc. were in danger of breaking their record for consecutive declines as investors express increasing caution over slowing sales of COVID vaccines.
With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 5
Amid dimming immediate prospects, the solar sector's long-term resilience could light the way for patient investors. Moderna's post-pandemic journey unveils the stark reality of biotech's boom-and-bus

Why Moderna Stock Is Sinking This Week

05:14pm, Thursday, 19'th Oct 2023
Pfizer cut its outlook for its COVID-19 product sales, which made investors worry about Moderna's prospects. However, Moderna issued a statement reaffirming its full-year 2023 sales guidance.

3 Stocks That Are Dead in the Water

04:32pm, Thursday, 19'th Oct 2023
The stock market appears to be entering choppy waters as the year winds down. Between high inflation, unpredictable interest rates and an increasingly frightful geopolitical landscape, risk factors ab
Pfizer and Moderna recently launched updated coronavirus vaccines. The companies are monitoring current vaccine demand for clues about future sales potential.
Japan agreed to buy an additional 9 million COVID-19 vaccine doses from Pfizer and another 1 million doses from Moderna , the health ministry said on Thursday.
Shares of Moderna Inc. MRNA, -6.07% took a 5.9% beating toward a three-year low in afternoon trading Tuesday, enough to lead the S&P 500's SPX, -0.21% losers, and to put them on track to suffer yet an
Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.
The small-cap Russell 2000, still under water over the past month, led the way higher today.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE